Trials / Completed
CompletedNCT06681805
Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section
Role of Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section: A Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Kafrelsheikh University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this work was to evaluate the role of prophylactic mirtazapine and different doses of intrathecal morphine in preventing nausea and vomiting.
Detailed description
It is common practice to provide intrathecal morphine to alleviate postoperative pain because of its powerful and long-lasting analgesic effects. Mirtazapine is a noradrenergic and specific serotonergic antidepressant. It is anxiolytic by its antagonist of the 5HT2 receptor and is strongly sleep-inducing. Its antagonist at 5-hydroxytryptamine subtype 3 (5-HT3) receptor may help to prevent nausea and vomiting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirtazapine + Bupivacaine + Morphine | Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5% along with 0.2 mg of morphine. |
| DRUG | Mirtazapine + Bupivacaine + Morphine | Patients received 30mg of oral mirtazapine one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine. |
| DRUG | Placebo + Bupivacaine + Morphine | Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.2 mg of morphine. |
| DRUG | Placebo+ Bupivacaine + Morphine | Patients received a placebo one hour before surgery plus 10 mg of bupivacaine 0.5%, along with 0.1 mg of morphine. |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-09-25
- Completion
- 2024-09-25
- First posted
- 2024-11-08
- Last updated
- 2024-11-08
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06681805. Inclusion in this directory is not an endorsement.